Abstract 960P
Background
HCC is an aggressive malignancy, accounting for ∼90% of primary hepatic cancers. While surgical resection and liver transplantation (Tx) can be curative, 8-20% of post-Tx and 40-70% of post-resection patients recur. Here we sought to analyze the utility of longitudinal testing with ctDNA in patients (pts) with HCC.
Methods
This multicenter study retrospectively analyzed 227 plasma samples from 66 pts with HCC. The curative-intent surgeries included liver Tx (41/66, 62%) and hepatectomy (23/66, 34%); two pts (3%) who were inoperable received liver directed and systemic targeted therapy. Five of the 41 post-Tx pts received additional resection for oligometastatic recurrence prior to ctDNA testing. The cohort was analyzed based on 3 mutually exclusive sub-cohorts: Cohort A (N=34): recurrence monitoring after curative liver Tx; Cohort B (N=25): recurrence monitoring after curative-intent surgical resection; Cohort C (N=7): pts with known recurrence monitored for treatment response/disease progression. Longitudinal ctDNA testing was performed using the SignateraTM bespoke mPCR NGS assay.
Results
The cohort distribution included: 28 (42.4%) / 21 (31.8%) / 7 (10.6%) / 9 (13.6%) stage I/II/III/IV pts with a median age of 67 years (range: 21-84); median follow-up of 584 days (range: 79 - 1537). In cohort A, all patients were ctDNA-negative and remained recurrence-free.In cohort B, postsurgical ctDNA was detected in 9 (36%) patients, 6 experienced clinical recurrence and 3 had limited follow-up. The median lead time of ctDNA detection over clinical recurrence was 52 days (range: 0-262). Among the ctDNA-negative patients (N=16), only one pt experienced clinical recurrence; this was >1 year after the last ctDNA test. In cohort C, on-treatment ctDNA dynamics were concordant with treatment response in 4 pts as measured by imaging. The remaining 3 pts were persistently ctDNA-negative on/shortly after systemic therapy.
Conclusions
Longitudinal testing with ctDNA is critical in identifying early recurrence post surgical resection. Similarly, monitoring treatment response in the palliative setting can help resolve ambiguous imaging results.
Clinical trial identification
N/A
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Brdiges: Financial Interests, Institutional, Advisory Board, Full-time employment and stock or option to own stock at Natera, Inc. Name: Antony Tin: Natera, Inc.. T. Tin, C. Brewer, A. Jurdi, M.C. Liu: Financial Interests, Personal and Institutional, Advisory Board: Natera Inc. All other authors have declared no conflicts of interest.
Resources from the same session
956P - Phase II study of adjuvant tislelizumab combined with interferon-α and active surveillance in hepatocellular carcinoma patients with microvascular invasion
Presenter: Yixiu Wang
Session: Poster session 18
957P - Interim report of Notable-HCC: A phase Ib study of neoadjuvant PD-1 with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma (HCC)
Presenter: Mingming Li
Session: Poster session 18
959P - Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma (HCC): Results from a phase II clinical trial
Presenter: Lixia Ma
Session: Poster session 18
961P - Blood circulating Galectin-3 is a prognostic biomarker in hepatocellular carcinoma
Presenter: Shadi Chamseddine
Session: Poster session 18
962P - SBRT improves the efficacy of immuno-checkpoint inhibitors for hepatocellular carcinoma through the activation of IL-6/JAK1-STAT3/PD-L1 axis mediated by MBD3 degradation
Presenter: Weiwei Yan
Session: Poster session 18
963P - Discovery and validation of cfDNA methylation, AFP and ctDNA mutation for the early detection of hepatocellular carcinoma: A multicenter prospective study (ASCEND-Hep)
Presenter: Mingxin Pan
Session: Poster session 18
966P - Potential role of neuropilin-1 in the prognosis, development and risk of invasion in hepatocellular carcinoma patients
Presenter: Tania Payo-Serafín
Session: Poster session 18
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18